Nasal Polyposis Treatment Market

Market Insights on Nasal Polyposis Treatment covering sales outlook, demand forecast & up-to-date key trends

Nasal Polyposis Treatment Market by Type of Treatment, End User & Region | Forecast 2023 to 2033

Nasal Polyposis Treatment Market Snapshot (2023 to 2033)

Expected to be valued at US$ 4.6 billion by the end of 2023, the market for nasal polyposis treatment is likely to expand at a CAGR of 6.7% until 2033. By the conclusion of the 2023-2033 forecast period, a valuation of US$ 8.8 billion is anticipate for nasal polyposis treatment.

Growing prevalence of chronic rhinosinusitis with nasal polyps especially in elderly population is one of the major factors propelling industry growth. Surging inflammatory diseases around the world is also expected to contribute to growth of nasal polyposis market.

Advancements in technology for removal of nasal polyps and increase in research and development is expected to lead to novel therapeutic treatment for nasal polyps which will lead to market expansion.

Report Attribute	Details
Expected Market Value (2023)	US$ 4.6 billion
Anticipated Forecast Value (2033)	US$ 8.8 billion
Projected Growth Rate (2023 to 2033)	CAGR 6.7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Nasal Polyposis treatment management Demand Analysis vs. Forecast 2023 to 2033

The market for Nasal Polyposis treatment was worth US$ 3.7 billion in 2018, while growing at a CAGR of 4.45% during the historical period. With each passing decade, extensive research & development activities are being conducted by healthcare professionals. These have translated into extensive clinical trials for potential drug candidates, or the introduction of novel therapies and diagnostics, which is expected to provide impetus to the market. For example, Hoffmann-La Roche completed its Phase III study on March 11, 2019, which was conducted to test effectiveness and safety of omalizumab in comparison with placebo in patients having chronic rhinosinusitis with nasal polyps who have witnessed insufficient response to standard treatments.

On the other hand, advancements in technology, such as nasal endoscopy and computerized tomography, better-quality healthcare facilities with innovative drug development for treatment of nasal polyps, and initiatives by governments in spreading awareness about nasal polyps, is expected to witness lucrative growth in market of Nasal polyposis during the projected period.

The growth in the number of rhinitis therapeutics distributed through the retail pharmacies and increasing number of these pharmacies in developed countries is anticipated to create opportunities and space for market expansion. In addition, patients generally opt for retail pharmacies for purchasing drugs, as these are easily accessible. Thus, presenting opportunities for future growth of nasal polyposis market.

After a comprehensive analysis of above-mentioned factors, the market for nasal polyposis is projected to attain a valuation of USD 8.8 billion by end of the forecast period, while exhibiting a CAGR of 6.7%.

Which are Some Prominent Drivers of the Nasal Polyposis treatment market?

The adoption of pipeline therapies in Nasal polyposis market like Fasenra (benralizumab), Tezepelumab, CBP-201, and others are expected to fuel growth of the market in the forecast period. With the launch of Fasenra (benralizumab) in 2022 and expected launch of Tezepelumab this year, the market is anticipated to witness growth during the forecast period. Both Fasenra and Tezepelumab is estimated to garner nearly USD 5 million in the first year of its launch which will aid in the expansion of targeted industry.

The recommendation from regulatory bodies for approval of authorised new drugs used in nasal polyposis treatment, is also anticipated to propel growth of this market, during the forecast period. For example, in June, 2020, Novartis got a positive recommendation on Xolair, its approved product. It is used for the treatment of adults who are suffering from serious chronic rhinosinusitis with nasal polyps. Likewise, Xolair is used for treating nasal polyps targeting and blocking immunoglobulin E (IgE), that aids in decreasing the size of nasal polyps. This will support market expansion.

With ab expected increase in the launch of biologics in the upcoming years, the ratio of patients opting for surgery might decline because of the excellent effectiveness of biologics and also fewer possibility of recurrence of the disease, augmenting the industry’s growth. Furthermore, the surge in market size of Nasal Polyposis is a direct result of the anticipated approval of emerging therapies and the rising Nasal Polyposis patient population.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

Dearth of Skilled Professionals and High Cost of Treatment will restrain market growth

Dearth of skilled and qualified healthcare professionals who are not able to treat these patients with appropriate treatments could hold back growth of the global nasal polyposis drugs market during the projected period. The massive expenditure associated with nasal polyposis treatment is also expected to hinder market expansion.

On the other hand, factors such as bleeding, visual disturbances, inflammation, and cerebrospinal fluid leak linked with surgical removal of nasal polyposis and several adverse reactions because of steroid therapy, may restrain market growth.

Region-Wise Insights

How will Nasal Polyposis Treatment progress across North America?

Rising Incidence of Chronic Rhinosinusitis to encourage Patients to Opt for Treatment

North America is anticipated to dominate the nasal polyposis treatment market, capturing a 41.5% market share. This region is projected to reflect a CAGR of 6.1% from 2023 to 2033. The growth is attributable to increasing incidence of several cancers and allergic disorders like asthma, sinusitis, and others. Moreover, research activities in the United States coupled with surging approvals from regulatory bodies are anticipated to fuel growth of this market during the projected period.

The presence of a huge target population, affected by chronic rhinosinusitis with nasal polyposis and rising sinus surgeries conducted in the United States are the major factors attributed to hold dominance in this region. Additionally, the approvals by the Federal Agency for the reimbursement of money used for treatment of nasal polyps will aid in regional market expansion.

For example, in June 2020, Intersect ENT, a medical device company, was approved by Centers for Medicare and Medicaid Services to SINUVA Sinus Implant for reimbursement, with a New C–Code. Likewise, New C Code for SINUVA will simplify the reimbursement process for ENT physicians and their practices which will boost regional market expansion. It will provide Medicare patients easier access to this novel drug eluting sinus implant. This will support in regional expansion of the market.

What is the Growth Outlook for Nasal Polyposis Treatment in the Asia Pacific?

Healthcare Providers finding Ground amid Increased Cases of Respiratory Disorders

According to Future Market Insights, Asia Pacific is expected to register a CAGR of 7% during the forecast period ranging from 2023 to 2033, with respect to treatment for nasal polyposis. The growth is expected to be driven by prevalence of allergic disorders and stable growth of the pharmaceutical industry in recent years. Moreover, China plays a crucial role in the Asia pacific region owing to its high population and high degree of government initiatives in the healthcare sector. Also, Ongoing trials in this region are expected to further stimulate market growth.

The presence of a large patient pool suffering from inflammatory and respiratory disorders in developing countries such as China and India, and growth in sinus surgeries conducted in developed countries in the region, are expected to fuel the nasal polyposis treatment market.

Similarly, increasing number of patients affected by nasal polyposis, government initiatives to promote awareness, and increasing demand for treatment are some of the other factors responsible for market expansion in this region. Presence of huge population is also one of the factors anticipated to positively influence nasal polyposis industry growth.

Category wise Insights

Based on Type of Treatment, which approach are Patients likely to Opt for?

Demand for Corticosteroids to Surge Prolifically in the Coming Decade

By type of treatment, corticosteroids are projected to account for 55% of all approaches. It is projected to witness CAGR of 9% during the forecast period. The growth is attributed to rising demand for corticosteroids treatment and its availability in numerous dosage forms such as injections, intranasal sprays, and drops according to suitability of the patient.

Furthermore, the availability of various corticosteroids as topical formulations and aerosols which have the ability to reduce the size of nasal polyposis, and therefore heal the nasal polyps in suffered patients is expected to contributed in significant share of market revenue. Likewise, Nasonex (mometasone) and Xhance (fluticasone propionate) are two major corticosteroid brands available in the market that will boost market growth. Also, patient compliance for creams is more compared to other dosage forms. This will aid in growth of the segment during the forecast period.

Which End User will likely comprise the Bulk of all Nasal Polyposis Treatment?

Hospitals to be the Primary Point of Contact for seeking Nasal Polyposis Treatment

Hospitals are anticipated to lead the market when it comes to seeking treatment for nasal polyps, with an expected market share of 64.2%. The growth of this segment is attributed to surging demand for sinus surgeries for the removal of nasal polyposis, leading to increased hospitalization and extensive range of services provided by hospitals at a single site.

Start-ups in the Nasal Polyposis Treatment Market

Start-ups help in understanding the outlook of any market. Start-ups also have the potential to generate higher returns which directly benefits in expansion of any market. This is because these are typically more efficient at converting inputs into outputs. These are more flexible and adaptable, able to shift quickly in response to changing market conditions. Some of the start-ups that will aid in expansion of Nasal Polyposis treatment market are:

Laurimed is a redwood, United states-based start-up that has developed physician-based devices to remove nasal polyps without the requirement for invasive surgery. The device PolypVac is an FDA 510(k) cleared (K163247) micro debrider, specifically designed to eliminate nasal polyps in the ENT office; Its products are available in two sizes - 3.3 mm and 4.0 mm. The tip of the device is designed to be flexible with multi-angle, malleable and 360? rotatable shaft. This company also offers Cliq Pump, which provides suction airflow. This company was founded in 2005.
Founded in 2003, Intersect ENT is a Menlo Park, United states-based start-up. This company is developer of a drug-releasing implant for the treatment of sinusitis. The company has developed drug-releasing implants called CE marked and FDA-approved dissolvable implants for the treatment of chronic sinusitis knowns as Propel, Propel Mini and PROPEL Contour. The company has claimed that the device is clinically proved to prevent obstruction of the ethmoid sinus following surgery. This firm has obtained total funding of US$ 76.5 million over four rounds. The latest funding round was held on May11, 2020 in which it was granted US$ 65 million. The main investors in this start-up are Norwest Venture Partners, USA Venture Partners, Kleiner Perkins, PTV Healthcare Capital, Deerfield and 4 others.

Market Competition

The nasal polyposis treatment market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of nasal polyps. This is expected to propel nasal polyposis treatment market. The major players in the market are: Sanofi, Merck & Co, Inc., OptiNose US, Inc., Intersect ENT, Inc., Pfizer, Regeneron Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Inc.

Some recent developments in the market are:

Key market players are concentrating on adoption of inorganic growth strategies such as acquisition, partnerships, and collaboration in order to improve its product portfolio. This is anticipated to drive the global Nasal Polyposis treatment market.

In July 2021, GSK plc. declared that Nucala (Mepolizumab) is approved by United states FDA for chronic bilateral nasal polyposis related with chronic rhinosinusitis. Also, the company’s investigational site at Boise, Idaho, is working on a study to determine effectiveness and safety of Depemokimab (GSK3511294) in patients suffering from chronic rhinosinusitis with nasal polyposis. It is presently doing phase 3 trial and will complete this study by January 2025.
In 2020, the United States Food and Drug Administration approved authorized use of Dupixent for adults with nasal polyps accompanied by chronic rhinosinusitis. It is the first treatment approved for uncontrolled chronic rhinosinusitis with nasal polyps and also reduces dependence on nasal polyp surgery and oral steroids.
In 2020, Roche Holding AG, a pharmaceutical company, had successfully completed and declared the positive result from two Phase III multicenter studies evaluating Xolair for the treatment of adults with chronic rhinosinusitis with nasal polyposis.??

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 4.6 billion
Market Value in 2033	US$ 8.8 billion
Growth Rate	CAGR of 6.7 % from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Type of Treatment End User Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East and Africa
Key Countries Profiled	United States Canada Brazil Mexico Germany United Kingdom France Spain Italy India China Japan South Korea Indonesia Singapore Thailand Australia New Zealand GCC Countries South Africa Israel
Key Companies Profiled	Sanofi S.A Merck & Co. Inc. OptiNose USA Inc. Intersect ENT Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. GSK plc. F. Hoffmann- La Roche Ltd. Teva Pharmaceutical Industries Inc. Novartis AG
Customization	Available Upon Request

Key Segments Profiled in the Nasal Polyposis Treatment Industry Survey

By Type of Treatment:

Pharmacological Therapies
- Corticosteroids
- Antibiotics
- Leukotriene Inhibitors
- Others
Surgeries
- Polypectomy
- Functional Endoscopic Sinus Surgery

By End User:

Hospitals
Ambulatory Surgical Centers
Specialty Clinics

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Frequently Asked Questions

What is the expected market value for nasal polyposis treatment as of 2023?

Future Market Insights expects the nasal polyposis treatment market to assume a valuation of US$ 4.6 billion

At what rate will the nasal polyposis treatment market grow from 2023 to 2033?

From 2023 to 2033, demand for nasal polyposis treatment is forecast to expand at a 6.7% CAGR

According to FMI, what is the expected market value for nasal polyposis treatment in 2033?

By 2033, the market for nasal polyposis treatment is likely to reach a value of US$ 8.8 billion

What was the registered growth rate of the market for nasal polyposis treatment from 2018 to 2022?

During the 2018-2022 historical period, the nasal polyposis treatment industry grew at a CAGR of 4.45%

How attractive are growth prospects for nasal polyposis treatment across North America?

In North America, the scope for nasal polyposis treatment is immense, likely to account for over 41% of all procedures

Will Asia Pacific offer expansion prospects for nasal polyposis treatment in the coming years?

FMI expects the market for nasal polyposis treatment across the Asia Pacific to expand at a CAGR of 7% from 2023 to 2033

By type of treatment, which approach is expected to be most sought after for treating nasal polyposis?

Corticosteroids-based nasal polyposis treatment is likely to remain popular, likely to grow at a CAGR of 9%

Which are some prominent nasal polyposis treatment providers?

Sanofi S.A., Merck & Co. Inc., Pfizer Inc., and GSK Plc. are some renowned healthcare companies offering nasal polyposis treatment

Table of Content

1. Executive Summary | Nasal Polyposis Treatment Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Type of Treatment, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type of Treatment, 2023 to 2033

5.3.1. Pharmacological Therapies

5.3.1.1. Corticosteroids

5.3.1.2. Antibiotics

5.3.1.3. Leukotriene Inhibitors

5.3.1.4. Others

5.3.2. Surgeries

5.3.2.1. Polypectomy

5.3.2.2. Functional Endoscopic Sinus Surgery

5.4. Y-o-Y Growth Trend Analysis By Type of Treatment, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Type of Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

6.3.1. Hospitals

6.3.2. Ambulatory Surgical Centres

6.3.3. Specialty Clinics

6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. Asia Pacific

7.3.5. Middle East and Africa

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. United States

8.2.1.2. Canada

8.2.2. By Type of Treatment

8.2.3. By End User

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Type of Treatment

8.3.3. By End User

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Type of Treatment

9.2.3. By End User

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Type of Treatment

9.3.3. By End User

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. United Kingdom

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Type of Treatment

10.2.3. By End User

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Type of Treatment

10.3.3. By End User

10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. China

11.2.1.2. Japan

11.2.1.3. South Korea

11.2.1.4. Singapore

11.2.1.5. Thailand

11.2.1.6. Indonesia

11.2.1.7. Australia

11.2.1.8. New Zealand

11.2.1.9. Rest of Asia Pacific

11.2.2. By Type of Treatment

11.2.3. By End User

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Type of Treatment

11.3.3. By End User

11.4. Key Takeaways

12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. GCC Countries

12.2.1.2. South Africa

12.2.1.3. Israel

12.2.1.4. Rest of Middle East and Africa

12.2.2. By Type of Treatment

12.2.3. By End User

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Type of Treatment

12.3.3. By End User

12.4. Key Takeaways

13. Key Countries Market Analysis

13.1. United States

13.1.1. Pricing Analysis

13.1.2. Market Share Analysis, 2022

13.1.2.1. By Type of Treatment

13.1.2.2. By End User

13.2. Canada

13.2.1. Pricing Analysis

13.2.2. Market Share Analysis, 2022

13.2.2.1. By Type of Treatment

13.2.2.2. By End User

13.3. Brazil

13.3.1. Pricing Analysis

13.3.2. Market Share Analysis, 2022

13.3.2.1. By Type of Treatment

13.3.2.2. By End User

13.4. Mexico

13.4.1. Pricing Analysis

13.4.2. Market Share Analysis, 2022

13.4.2.1. By Type of Treatment

13.4.2.2. By End User

13.5. Germany

13.5.1. Pricing Analysis

13.5.2. Market Share Analysis, 2022

13.5.2.1. By Type of Treatment

13.5.2.2. By End User

13.6. United Kingdom

13.6.1. Pricing Analysis

13.6.2. Market Share Analysis, 2022

13.6.2.1. By Type of Treatment

13.6.2.2. By End User

13.7. France

13.7.1. Pricing Analysis

13.7.2. Market Share Analysis, 2022

13.7.2.1. By Type of Treatment

13.7.2.2. By End User

13.8. Spain

13.8.1. Pricing Analysis

13.8.2. Market Share Analysis, 2022

13.8.2.1. By Type of Treatment

13.8.2.2. By End User

13.9. Italy

13.9.1. Pricing Analysis

13.9.2. Market Share Analysis, 2022

13.9.2.1. By Type of Treatment

13.9.2.2. By End User

13.10. China

13.10.1. Pricing Analysis

13.10.2. Market Share Analysis, 2022

13.10.2.1. By Type of Treatment

13.10.2.2. By End User

13.11. Japan

13.11.1. Pricing Analysis

13.11.2. Market Share Analysis, 2022

13.11.2.1. By Type of Treatment

13.11.2.2. By End User

13.12. South Korea

13.12.1. Pricing Analysis

13.12.2. Market Share Analysis, 2022

13.12.2.1. By Type of Treatment

13.12.2.2. By End User

13.13. Singapore

13.13.1. Pricing Analysis

13.13.2. Market Share Analysis, 2022

13.13.2.1. By Type of Treatment

13.13.2.2. By End User

13.14. Thailand

13.14.1. Pricing Analysis

13.14.2. Market Share Analysis, 2022

13.14.2.1. By Type of Treatment

13.14.2.2. By End User

13.15. Indonesia

13.15.1. Pricing Analysis

13.15.2. Market Share Analysis, 2022

13.15.2.1. By Type of Treatment

13.15.2.2. By End User

13.16. Australia

13.16.1. Pricing Analysis

13.16.2. Market Share Analysis, 2022

13.16.2.1. By Type of Treatment

13.16.2.2. By End User

13.17. New Zealand

13.17.1. Pricing Analysis

13.17.2. Market Share Analysis, 2022

13.17.2.1. By Type of Treatment

13.17.2.2. By End User

13.18. GCC Countries

13.18.1. Pricing Analysis

13.18.2. Market Share Analysis, 2022

13.18.2.1. By Type of Treatment

13.18.2.2. By End User

13.19. South Africa

13.19.1. Pricing Analysis

13.19.2. Market Share Analysis, 2022

13.19.2.1. By Type of Treatment

13.19.2.2. By End User

13.20. Israel

13.20.1. Pricing Analysis

13.20.2. Market Share Analysis, 2022

13.20.2.1. By Type of Treatment

13.20.2.2. By End User

14. Market Structure Analysis

14.1. Competition Dashboard

14.2. Competition Benchmarking

14.3. Market Share Analysis of Top Players

14.3.1. By Regional

14.3.2. By Type of Treatment

14.3.3. By End User

15. Competition Analysis

15.1. Competition Deep Dive

15.1.1. Sanofi S.A

15.1.1.1. Overview

15.1.1.2. Product Portfolio

15.1.1.3. Profitability by Market Segments

15.1.1.4. Sales Footprint

15.1.1.5. Strategy Overview

15.1.1.5.1. Marketing Strategy

15.1.2. Merck & Co, Inc.

15.1.2.1. Overview

15.1.2.2. Product Portfolio

15.1.2.3. Profitability by Market Segments

15.1.2.4. Sales Footprint

15.1.2.5. Strategy Overview

15.1.2.5.1. Marketing Strategy

15.1.3. OptiNose US, Inc.

15.1.3.1. Overview

15.1.3.2. Product Portfolio

15.1.3.3. Profitability by Market Segments

15.1.3.4. Sales Footprint

15.1.3.5. Strategy Overview

15.1.3.5.1. Marketing Strategy

15.1.4. Intersect ENT, Inc.

15.1.4.1. Overview

15.1.4.2. Product Portfolio

15.1.4.3. Profitability by Market Segments

15.1.4.4. Sales Footprint

15.1.4.5. Strategy Overview

15.1.4.5.1. Marketing Strategy

15.1.5. Pfizer Inc

15.1.5.1. Overview

15.1.5.2. Product Portfolio

15.1.5.3. Profitability by Market Segments

15.1.5.4. Sales Footprint

15.1.5.5. Strategy Overview

15.1.5.5.1. Marketing Strategy

15.1.6. Regeneron Pharmaceuticals, Inc.

15.1.6.1. Overview

15.1.6.2. Product Portfolio

15.1.6.3. Profitability by Market Segments

15.1.6.4. Sales Footprint

15.1.6.5. Strategy Overview

15.1.6.5.1. Marketing Strategy

15.1.7. Novartis AG

15.1.7.1. Overview

15.1.7.2. Product Portfolio

15.1.7.3. Profitability by Market Segments

15.1.7.4. Sales Footprint

15.1.7.5. Strategy Overview

15.1.7.5.1. Marketing Strategy

15.1.8. GlaxoSmithKline plc

15.1.8.1. Overview

15.1.8.2. Product Portfolio

15.1.8.3. Profitability by Market Segments

15.1.8.4. Sales Footprint

15.1.8.5. Strategy Overview

15.1.8.5.1. Marketing Strategy

15.1.9. F. Hoffmann-La Roche Ltd

15.1.9.1. Overview

15.1.9.2. Product Portfolio

15.1.9.3. Profitability by Market Segments

15.1.9.4. Sales Footprint

15.1.9.5. Strategy Overview

15.1.9.5.1. Marketing Strategy

15.1.10. Teva Pharmaceutical Industries Inc

15.1.10.1. Overview

15.1.10.2. Product Portfolio

15.1.10.3. Profitability by Market Segments

15.1.10.4. Sales Footprint

15.1.10.5. Strategy Overview

15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Type of Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Type of Treatment, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Type of Treatment, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Type of Treatment, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Type of Treatment, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: Middle East and Africa Market Value (US$ Million) Forecast by Type of Treatment, 2018 to 2033

Table 18: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2018 to 2033

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Type of Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Type of Treatment, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Type of Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Type of Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 13: Global Market Attractiveness by Type of Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by End User, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Type of Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Type of Treatment, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Type of Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Type of Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 28: North America Market Attractiveness by Type of Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by End User, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Type of Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Type of Treatment, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Type of Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Type of Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Type of Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Type of Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Type of Treatment, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Type of Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Type of Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 58: Europe Market Attractiveness by Type of Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by End User, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Type of Treatment, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by End User, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Type of Treatment, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Type of Treatment, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Type of Treatment, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Type of Treatment, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by End User, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: Middle East and Africa Market Value (US$ Million) by Type of Treatment, 2023 to 2033

Figure 77: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033

Figure 78: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: Middle East and Africa Market Value (US$ Million) Analysis by Type of Treatment, 2018 to 2033

Figure 83: Middle East and Africa Market Value Share (%) and BPS Analysis by Type of Treatment, 2023 to 2033

Figure 84: Middle East and Africa Market Y-o-Y Growth (%) Projections by Type of Treatment, 2023 to 2033

Figure 85: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 86: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 87: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 88: Middle East and Africa Market Attractiveness by Type of Treatment, 2023 to 2033

Figure 89: Middle East and Africa Market Attractiveness by End User, 2023 to 2033

Figure 90: Middle East and Africa Market Attractiveness by Country, 2023 to 2033